Citations

Clear

6274 citation(s) found for "To, Andrew".

Respiratory Characteristics of Pulmonary Toxicity and Pneumocystis Pneumonia Associated with Bleomycin Use for Hodgkin Lymphoma
Barreto, J.N., Thompson, Carrie A. , Pawlenty, Amanda G. , Potter, Ashley , Tosh, Pritish K. , Wieruszewski, Patrick M. , Mara, Kristin C. , Limper, Andrew H.

Mayo Clinic

D44. AUTOIMMUNE AND DRUG INDUCED LUNG DISEASE | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6846-A6846

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6846 Get It

NCCN Guidelines Insights: Rectal Cancer, Version 6.2020
Benson, Al B. , Al-Hawary, Mahmoud M. , Arain, Mustafa A., Chen, Yi‐Jen , Ciombor, Kristen K. , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hoffe, Sarah E. , Hunt, Steven R., Kirilcuk, Natalie, Krishnamurthi, Smitha , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Miller, Eric D. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Pedersen, Katrina S. , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Willett, Christopher G. , Johnson-Chilla, Alyse, Gurski, Lisa A., Hubbard, Joleen, Miller, Eric D. , Meyerhardt, Jeffrey A , Pedersen, Katrina , Venook, Alan P. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Parikh, Aparna R. , Patel, Hitendra, Saltz, Leonard B. , Schneider, Charles John , Stoffel, Elena M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 7, 2020 | Volume: 18 | Issue: 7 | Pages: 806-815

10.6004/jnccn.2020.0032 | PMID 32634771 Get It

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E– or HER2 amplification–positive disease.
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, David G. , Spencer, Sharon, Adelstein, David J. , Brizel, David M. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Fenton, Moon J. , Foote, Robert L. , Galloway, Thomas J. , Gillison, Maura L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Weber, Randal S. , Weinstein, Gregory S., Witek, Matthew E. , Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Brizel, David M , Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Adkins, Douglas R. , Anzai, Yoshimi , Bruce, Justine Y. , Caudell, Jimmy J , Colevas, Alexander Dimitrios , Ridge, John Andrew , Shah, Jatin P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 7, 2020 | Volume: 18 | Issue: 7 | Pages: 873-898

10.6004/jnccn.2020.0031 | PMID 32634781 Get It

Treatment is complex for patients with head and neck (H&N) cancers with specific site of disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning for H&N cancers involves a multidisciplinary team of experts. This article describes supportive care recommendations in the NCCN Guidelines for Head and Neck Cancers, as well as the rationale supporting a new section on imaging recommendations for patients with H&N cancers. This article also describes updates to treatment recommendations for patients with very advanced H&N cancers and salivary gland tumors, specifically systemic therapy recommendations.
Divergence in Timing and Magnitude of Testosterone Levels Between Male and Female Youths
Senefeld, Jonathon W. , Coleman, Doriane Lambelet, Carter, Rickey E. , Clayburn, Andrew J. , Joyner, Michael J. , Johnson, Patrick W. , Carter, Rickey E , Joyner, Michael J , Senefeld, Jonathon W

Mayo Clinic

JAMA | July 7, 2020 | Volume: 324 | Issue: 1 | Pages: 99

10.1001/jama.2020.5655 | PMID 32633795 Get It

Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD
Kunchok, Amy , Snyder, Melissa R. , Saadeh, Ruba , Chen, John J. , Weinshenker, Brian G. , Pittock, Sean J. , Flanagan, E P , Pittock, S J , Weinshenker, Brian G , Pittock, Sean J , Chen, John J , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Multiple Sclerosis Journal | July 7, 2020 | Volume: 27 | Issue: 4 | Pages: 630-635

10.1177/1352458520933884 | PMID 32633603 Get It

Aquaporin-4 (AQP4) neuromyelitis optica spectrum disorder (NMOSD) has been demonstrated to be associated with non-organ and organ-specific autoantibodies (antinuclear antibody, extractable nuclear antibody, double-stranded DNA, muscle acetylcholine receptor antibody) and systemic autoimmune diseases. In this study, we evaluated whether a similar association with non-organ and organ-specifc autoantibodies occurs in patients with MOG-IgG1-associated disorders. We determined that MOG-IgG1 was not strongly associated with these organ and non-organ-specific autoantibodies. Systemic lupus erythematous (SLE) was significantly associated with AQP4-IgG+ NMOSD and not with MOGAD ( p = 0.037). These findings suggest differences in co-existing systemic and organ-specific autoimmunity between MOGAD and AQP4-IgG+ NMOSD.
Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis
Wagner, Tyler , Shweta, Fnu , Awasthi, Samir , Bade, Sairam, Puranik, Arjun, Kang, Martin , Pickering, Brian W. , O’Horo, John C. , Vergidis, Paschalis , Temesgen, Zelalem , Rizza, Stacey A. , Mahmood, Maryam , Wilson, Walter R. , Liebers, Matt, Doctor, Zainab M., Silvert, Eli , Solomon, Hugo, Barve, Rakesh , Williams, Amy W. , Morice, William G. , Badley, Andrew D. , Venkatakrishnan, A J , O'Horo, John C, Rizza, Stacey , Challener, Douglas , Anand, Praveen , Badley, Andrew, Soundararajan, Venky , Badley, Andrew D , O'Horo, John C , Vergidis, Paschalis , Mahmood, Maryam , Shweta, Fnu , Wagner, Tyler, Murugadoss, Karthik , Bauer, Philippe R. , Razonable, Raymund R. , Challener, Douglas W. , Anand, Praveen , Anand, Akash, Gores, Gregory J. , Morice, William George , Halamka, John , Soundararajan, Venky

Mayo Clinic

eLife | July 7, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.58227 | PMID 32633720 Get It

Understanding temporal dynamics of COVID-19 symptoms could provide fine-grained resolution to guide clinical decision-making. Here, we use deep neural networks over an institution-wide platform for the augmented curation of clinical notes from 77,167 patients subjected to COVID-19 PCR testing. By contrasting Electronic Health Record (EHR)-derived symptoms of COVID-19-positive (COVID pos ; n = 2,317) versus COVID-19-negative (COVID neg ; n = 74,850) patients for the week preceding the PCR testing date, we identify anosmia/dysgeusia (27.1-fold), fever/chills (2.6-fold), respiratory difficulty (2.2-fold), cough (2.2-fold), myalgia/arthralgia (2-fold), and diarrhea (1.4-fold) as significantly amplified in COVID pos over COVID neg patients. The combination of cough and fever/chills has 4.2-fold amplification in COVID pos patients during the week prior to PCR testing, in addition to anosmia/dysgeusia, constitutes the earliest EHR-derived signature of COVID-19. This study introduces an Augmented Intelligence platform for the real-time synthesis of institutional biomedical knowledge. The platform holds tremendous potential for scaling up curation throughput, thus enabling EHR-powered early disease diagnosis.
Impact of disconnected pancreatic duct syndrome on endoscopic ultrasound-guided drainage of pancreatic fluid collections
Wang, Lillian , Elhanafi, Sherif , Topazian, Mark , Majumder, Shounak , Levy, Michael J. , Petersen, Bret T. , Martin, John A. , Chari, Suresh T. , Vege, Santhi Swaroop , Abu Dayyeh, Barham K, Vege, Santhi S, Majumder, Shounak , Chari, Suresh T , Storm, Andrew C. , Dayyeh, Barham K. Abu , Levy, Michael J. , Chandrasekhara, Vinay

Mayo Clinic

Endoscopy | July 6, 2020 | Volume: 53 | Issue: 06 | Pages: 603-610

10.1055/a-1213-1489 | PMID 32629484 Get It

Abstract Background Endoscopic intervention for pancreatic fluid collections (PFCs) with disconnected pancreatic duct syndrome (DPDS) has been associated with failures and increased need for additional endoscopic and non-endoscopic interventions. The primary aim of this study was to determine the outcomes of endoscopic ultrasound (EUS)-guided transmural drainage of PFCs in patients with DPDS. Methods In patients undergoing EUS-guided drainage of PFCs from January 2013 to January 2018, demographic profiles, procedural indications and details, adverse events, outcomes, and subsequent interventions were retrospectively collected. Overall treatment success was determined by PFC resolution on follow-up imaging or stent removal without recurrence. Results EUS-guided drainage of PFCs was performed in 141 patients. DPDS was present in 57 of them (40 %) and walled-off necrosis was the most frequent type of PFC (55 %). DPDS was not associated with lower clinical success, increased number of repeat interventions, or increased time to PFC resolution. Patients with DPDS were more likely to be treated with permanent transmural plastic double-pigtail stents (odds ratio [OR] 6.4; 95 % confidence interval [CI] 2.5 – 16.5; P < 0.001). However, when stents were removed, DPDS was associated with increased PFC recurrence after stent removal (OR 8.0; 95 %CI 1.2 – 381.8; P = 0.04). Conclusions DPDS frequently occurs in patients with PFCs but does not negatively impact successful resolution. DPDS is associated with increased PFC recurrence after stent removal.
Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways
Eng, Oliver S. , Blakely, Andrew M. , Lafaro, Kelly J. , Fackche, Nadege , Powers, Benjamin D. , Hendrix, Ryan J. , Lambert, Laura , Walle, Kara Vande, Leiting, Jennifer L. , Dhar, Vikrom K. , Baumgartner, Joel , Lowy, Andrew M. , Zaidi, Mohammad Y. , Staley, Charles A., Kimbrough, Charles W. , Cloyd, Jordan M. , Lee, Byrne , Raoof, Mustafa , Powers, Benjamin , Grotz, Travis E , Leiting, Jennifer L , Patel, Sameer H , Clarke, Callisia N , Mogal, Harveshp , Raoof, Mustafa , Dhar, Vikrom , Fournier, Keith F. , Johnston, Fabian M , Dineen, Seán , Ronnekleiv-Kelly, Sean M , Grotz, Travis E. , Clarke, Callisia N.

Mayo Clinic

Journal of Surgical Oncology | July 6, 2020 | Volume: 122 | Issue: 5 | Pages: 980-985

10.1002/jso.26099 | PMID 32627199 Get It

AbstractBackgroundVariations in care have been demonstrated both within and among institutions in many clinical settings. By standardizing perioperative practices, Enhanced Recovery After Surgery (ERAS) pathways reduce variation in perioperative care. We sought to characterize the variation in cytoreductive surgery (CRS)/heated intraperitoneal chemotherapy (HIPEC) perioperative practices among experienced US medical centers.MethodsData from the US HIPEC Collaborative represents a retrospective multi‐institutional cohort study of CRS and CRS/HIPEC procedures performed from 12 major academic institutions. Patient characteristics and perioperative practices were reported and compared. Institutional variation was analyzed using hierarchical mixed‐effects linear (continuous outcomes) or logistic (binary outcomes) regression models.ResultsA total of 2372 operations were included. CRS/HIPEC was performed most commonly for appendiceal histologies (64.2%). The rate of complications (overall 56.3%, range: 31.8‐70.9) and readmissions (overall 20.6%, range: 8.9‐33.3) varied by institution (P < .001). Institution‐level variation in perioperative practice patterns existed among measured ERAS pathway process/outcomes (P < .001). The percentages of variation with each process/outcome measure attributable solely to institutional practices ranged from 0.6% to 66.6%.ConclusionsSignificant variation exists in the perioperative care of patients undergoing CRS/HIPEC at major US academic institutions. These findings provide a strong rationale for the investigation of best practices in CRS/HIPEC patients.
Inner Ear Enhancement With Delayed 3D-FLAIR MRI Imaging in Vestibular Schwannoma
Carlson, Matthew L. , Lane, John I. , Bowen, Andrew J.

Mayo Clinic

Otology & Neurotology | July 5, 2020 | Volume: 41 | Issue: 9 | Pages: 1274-1279

10.1097/mao.0000000000002768 | PMID 32925857 Get It

Objectives: To evaluate blood–labyrinth barrier permeability using delayed gadolinium enhanced three-dimensional fluid-attenuated inversion recovery (3D-FLAIR) in patients with untreated sporadic vestibular schwannoma (VS) to interrogate the etiopathogenesis of progressive sensorineural hearing loss. Design: Prospective case series. Setting: Single institution tertiary care center. Participants: Patients with previously untreated small to medium-sized unilateral VS undergoing 3D-FLAIR imaging 10 minutes (immediate) and 5 to 8 hours (delayed) after administration of intravenous gadolinium. Main Outcome Measures: Comparison of cochlear and vestibular signal intensity ratios (SIRs) across immediate and delayed images and across the tumor and nontumor ear. Results: Six of eight (75%) patients demonstrated asymmetric enhancement of inner ear structures on delayed contrast-enhanced imaging. Delayed mean cochlea and vestibule SIRs were significantly greater than immediate SIRs (cochlea: 1.91 versus 1.21 [p = 0.02]; vestibule 1.74 versus 1.15 [p = 0.02]). A higher vestibule SIR was statistically significantly associated with poorer pure-tone average and word recognition scores (p = 0.001). Conclusion: Ears with VS exhibited increased enhancement on delayed 3D FLAIR imaging. These findings suggest that alterations in blood–labyrinth barrier permeability may explain progressive sensorineural hearing loss in a subset of patients with untreated VS.
Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma
Barreto, Jason N. , Thompson, Carrie A. , Wieruszewski, Patrick M. , Pawlenty, Amanda G. , Mara, Kristin C. , Potter, Ashley , Tosh, Pritish K. , Limper, Andrew H. , Potter, Ashley L , Sierzchulski, Amanda G. , Tosh, Pritish , Limper, Andrew H , Mara, Kristin C , Wieruszewski, Patrick M

Mayo Clinic

Leukemia & Lymphoma | July 5, 2020 | Volume: 61 | Issue: 11 | Pages: 2622-2629

10.1080/10428194.2020.1786561 | PMID 32623928 Get It